The OncoStent scaffold enables highly effective therapy after minimally invasive implantation. Special proteins bind and modify metastatic cancer cells before they can metastasize in the liver. Another therapeutic approach is based on the recruitment of immune and tumor cells in the scaffold in order to increase the effector: target ratio.
The OncoStent scaffold acts as a so-called “gatekeeper” for the liver aiming at sustained liver function to significantly improve the quality of life of the critical ill patient.